Moody Aldrich Partners LLC Decreases Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

Moody Aldrich Partners LLC reduced its stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 43.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 67,415 shares of the company’s stock after selling 51,872 shares during the period. Moody Aldrich Partners LLC owned about 0.11% of Protagonist Therapeutics worth $2,602,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of PTGX. Squarepoint Ops LLC purchased a new position in Protagonist Therapeutics in the 2nd quarter worth approximately $340,000. Millennium Management LLC increased its stake in shares of Protagonist Therapeutics by 2,135.6% during the second quarter. Millennium Management LLC now owns 958,283 shares of the company’s stock valued at $33,205,000 after buying an additional 915,418 shares during the period. The Manufacturers Life Insurance Company increased its stake in shares of Protagonist Therapeutics by 27.6% during the second quarter. The Manufacturers Life Insurance Company now owns 114,406 shares of the company’s stock valued at $3,964,000 after buying an additional 24,749 shares during the period. Northwestern Mutual Wealth Management Co. purchased a new position in shares of Protagonist Therapeutics during the second quarter valued at approximately $5,467,000. Finally, Cubist Systematic Strategies LLC increased its stake in shares of Protagonist Therapeutics by 1,304.5% during the second quarter. Cubist Systematic Strategies LLC now owns 84,202 shares of the company’s stock valued at $2,918,000 after buying an additional 78,207 shares during the period. 98.63% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, insider Suneel Gupta sold 103,437 shares of the company’s stock in a transaction on Monday, November 25th. The stock was sold at an average price of $46.04, for a total transaction of $4,762,239.48. Following the transaction, the insider now directly owns 256,174 shares of the company’s stock, valued at $11,794,250.96. This represents a 28.76 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Arturo Md Molina sold 1,906 shares of the company’s stock in a transaction on Friday, November 15th. The shares were sold at an average price of $40.98, for a total value of $78,107.88. Following the transaction, the insider now directly owns 46,444 shares in the company, valued at approximately $1,903,275.12. The trade was a 3.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 209,863 shares of company stock valued at $9,689,847 over the last ninety days. 5.40% of the stock is currently owned by corporate insiders.

Protagonist Therapeutics Trading Down 1.0 %

Protagonist Therapeutics stock opened at $37.99 on Wednesday. The business’s fifty day simple moving average is $39.96 and its two-hundred day simple moving average is $41.84. Protagonist Therapeutics, Inc. has a 12 month low of $24.22 and a 12 month high of $48.89. The company has a market capitalization of $2.26 billion, a price-to-earnings ratio of 14.28 and a beta of 2.23.

Protagonist Therapeutics (NASDAQ:PTGX) last released its earnings results on Thursday, November 7th. The company reported ($0.54) EPS for the quarter, topping the consensus estimate of ($0.59) by $0.05. Protagonist Therapeutics had a return on equity of 34.68% and a net margin of 52.76%. The business had revenue of $4.68 million for the quarter, compared to the consensus estimate of $4.50 million. On average, equities research analysts predict that Protagonist Therapeutics, Inc. will post 2.28 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. Wedbush reissued an “outperform” rating and set a $58.00 target price on shares of Protagonist Therapeutics in a research note on Tuesday, November 19th. BMO Capital Markets assumed coverage on Protagonist Therapeutics in a research note on Friday, December 6th. They set an “outperform” rating and a $62.00 target price on the stock. HC Wainwright restated a “buy” rating and set a $50.00 price target on shares of Protagonist Therapeutics in a research report on Tuesday, December 10th. StockNews.com lowered Protagonist Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, December 10th. Finally, The Goldman Sachs Group assumed coverage on Protagonist Therapeutics in a research report on Friday, December 6th. They set a “neutral” rating and a $47.00 price target on the stock. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $53.78.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.